CXCR4 and ovarian cancer: We demonstrated that combination therapy with AMD3100 targeting CXCL12-CXCR4 and the conventional drug cisplatin significantly reduced overall burden of ovarian cancer cells in the abdomen relative to treatment with either agent alone or vehicle control.